Navigation Links
Dipeptidyl in Medical News

Two Studies at AACE 2009 Annual Meeting Highlight Effects of Welchol(R) (colesevelam HCl) on Blood Glucose and LDL-C in Patients with Type 2 Diabetes

... 1 diabetes or for the treatment of diabetic ketoacidosis. - Welchol has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones. - Welchol has not been studied in Fredrickson Typ...

Takeda Receives New Information on Alogliptin (SYR-322) NDA

...vered by Takeda's wholly owned U.S. subsidiary, Takeda San Diego, Inc. is a dipeptidyl peptidase IV (DPP-4) inhibitor being reviewed as an adjunct to diet and exe...abetes. About DPP-4 Inhibitors DPP-4 inhibitors inhibit the enzyme dipeptidyl peptidase IV (DPP-4), which metabolizes the insulin-increasing hormones glu...

GSK Initiates Phase III Programme for Novel Type 2 Diabetes Medication, Syncria(R) (albiglutide)

...ive comparators. A majority of the studies will include active comparators, including metformin, sulphonylurea, thiazolidinedione (TZD) insulin and a dipeptidyl peptidase four inhibitor (DPP IV). The study duration is expected to be two to three years and the main dose and regimen for the programme will be 30 ...

Amylin Pharmaceuticals Reports 2008 Financial Results

... Initiated DURATION-4 clinical study, comparing exenatide once weekly as a monotherapy treatment to either metformin, a thiazolidinedione (TZD) or a dipeptidyl peptidase-4 (DPP-4) inhibitor. Results from this study are expected in 2010. Corporate Implemented a strategic re...

New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes

...cular Outcomes (5.4) 07/2008 INDICATIONS AND USAGE JANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise ...IA Tablets contain sitagliptin phosphate, an orally-active inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme. Sitagliptin phosphate monohydrate is desc...

Phase 3 results for alogliptin

... 68th Scientific Sessions by Takeda Global Research & Development Center, Inc. Alogliptin, which has been shown to be a highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4), is currently under investigation as an oral treatment for type 2 diabetes. Alogliptin administered once daily demonstrated stati...

Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes

...t of type 1 diabetes or for the treatment of diabetic ketoacidosis. It has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones. Welchol has not been studied in Fredrickson Type I,...

Welchol(TM) Added to the American College of Endocrinology/American Association of Clinical Endocrinologists 'Road Maps to Achieve Glycemic Control in Patients with Type 2 Diabetes Mellitus'

...t of type 1 diabetes or for the treatment of diabetic ketoacidosis. It has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones. Welchol has not been studied in Fredrickson Type I,...

Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes

...t of type 1 diabetes or for the treatment of diabetic ketoacidosis. It has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones. Welchol has not been studied in Fredrickson Type I,...

Takeda submits new drug application for alogliptin (syr-322) in the US

...ed a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes. Discovered by Takeda San Diego, Inc., alogliptin was designed...
Dipeptidyl in Medical Technology

Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes

...mplete response letter from the U.S. Food and Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for alogliptin, a selective dipeptidyl peptidase IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise. In recent months, the FDA ...

Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes

...ns of people with type 2 diabetes." About LY2189265 LY2189265, a once-weekly injection, is a novel-engineered fusion protein, consisting of a dipeptidyl peptidase-IV (DDP-IV) protected GLP-1 analog linked to a fragment of immunoglobulin G4 that is believed to increase the duration of its pharmacologica...

Boehringer Ingelheim Unveils Diabetes Pipeline

...e Company is investigating compounds in Phase II and Phase III clinical development worldwide. New Phase II data results for linagliptin (BI 1356), a dipeptidyl peptidase 4 (DPP-4) inhibitor and the Company's lead diabetes compound, were presented today at the 69th Annual American Diabetes Association (ADA) Sc...

Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe

...rom the original plan of mid-2009 to 2012. Alogliptin, which was discovered by Takeda's wholly owned U.S. subsidiary, Takeda San Diego, Inc. is a dipeptidyl peptidase IV (DPP-4) inhibitor for the treatment of type 2 diabetes. By providing complementary mechanisms of action, alogliptin/ACTOS targets the cor...

Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback

...ION study. The DURATION-4 study examines exenatide once weekly as a monotherapy treatment compared to either metformin, a thiazolidinedione (TZD) or a dipeptidyl peptidase-4 (DPP-4) inhibitor. The double-blind study is expected to include approximately 800 patients and complete in 2010. "We are confiden...

New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder

...t of type 1 diabetes or for the treatment of diabetic ketoacidosis. It has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones. Welchol has not been studied in Fredrickson Type I,...

Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies

...) 68th Scientific Sessions by Takeda Global Research & Development Center, Inc. Alogliptin, which has been shown to be a highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4), is currently under investigation as an oral treatment for type 2 diabetes. Alogliptin administered once daily demonstrated statis...

Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated

...t of type 1 diabetes or for the treatment of diabetic ketoacidosis. It has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones. Welchol has not been studied in Fredrickson Type I,...

Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes

...t of type 1 diabetes or for the treatment of diabetic ketoacidosis. It has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones. Welchol has not been studied in Fredrickson Type I,...

Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.

...ed a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes. Discovered by Takeda San Diego, Inc., alogliptin was designed ...
Dipeptidyl in Medical Products

ACE - REA Hypertension / Cardiac Evaluation, Cardiovascular 001-RK-ACD Angiotensin Converting Enzyme

Description:... Angiotensin Converting Enzyme (ACE), also known as Kininase II, is a dipeptidyl carboxypeptidase (EC 3.4.15.1) with a molecular weight of at least 129,000. The structure of this glycoprotein shows a single polypeptide chain, a pol...
Company:ALPCO Diagnostics
Dipeptidyl in Biological Technology

FDA Continues Review of Takeda's New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes

...will work with the FDA as they continue this NDA review." Alogliptin is a dipeptidyl peptidase IV (DPP-4) inhibitor discovered by Takeda's wholly owned U.S. sub... to placebo. About DPP-4 Inhibitors DPP-4 inhibitors inhibit the enzyme dipeptidyl peptidase-4 (DPP-4), which selectively metabolizes the insulin-increasing h...
Dipeptidyl in Biological Products

Anti-Rat Dipeptidyl Peptidase IV (DPP IV) Monoclonal Antibody, Unconjugated, Clone 5E8 from Cell Sciences

Description: Anti-rat Dipeptidyl Peptidase IV (DPP IV), CD26, Clone 5E8, Monoclonal Antibody...
Company:Cell Sciences
Other Tags
(Date:5/6/2015)... (PRWEB) May 06, 2015 When it ... are considered more reputable and respected than those of ... advised by their physician lose more weight than those ... study conducted by the University of Georgia and ... Biology recently revealed that patients advised by their physicians ...
(Date:5/6/2015)... 2015 Spiking drug prices are taking large ... survey by The Senior Citizens League (TSCL). ... co-pays and co-insurance costs than expected in 2014 according to ... cost spikes may be tough for many beneficiaries to figure ... prices are commonly associated with brand and newer specialty drugs, ...
(Date:5/6/2015)... Launch Corporation, LLC. is pleased to announce that Launch Trampoline ... Tanguay Avenue. Owned and operated by Rick Arnold and Phil ... New England. , “We are extremely excited for Rick and ... and CEO of Launch. “They have established great roots in ... continue to establish that positive growth in the greater Nashua ...
(Date:5/6/2015)... The future of nursing is influenced by many ... increase in educational requirements. Leslie Brown, branch manager of ... on these trends and how a travel nurse ... exist in the nursing field. , Technology is ... been prevalent across the U.S. ever since the HITECH Act ...
(Date:5/6/2015)... 2015 LINET Americas has been awarded ... the small business category. The award was given for ... Award is given on an annual basis to foreign ... contributions to philanthropy. Since 1998, the Charlotte International ... the Mayor’s International Community Awards. The award was presented ...
Breaking Medicine News(10 mins):Health News:Diet Doc Unveils New Protocol Around Doctor Advised Weight Loss 2Health News:Diet Doc Unveils New Protocol Around Doctor Advised Weight Loss 3Health News:New Survey By The Senior Citizens League Reveals 61% Had Higher Than Expected Medicare Part D Costs In 2014 2Health News:New Survey By The Senior Citizens League Reveals 61% Had Higher Than Expected Medicare Part D Costs In 2014 3Health News:Jump Up and Celebrate: Launch Trampoline Park Opens in Nashua, NH 2Health News:National Nurses Week: Exciting Travel Nursing Trends Discussed with a Healthcare Staffing Expert 2Health News:National Nurses Week: Exciting Travel Nursing Trends Discussed with a Healthcare Staffing Expert 3Health News:National Nurses Week: Exciting Travel Nursing Trends Discussed with a Healthcare Staffing Expert 4Health News:LINET Americas Wins The Mayor's International Community Award in Charlotte 2
(Date:4/1/2015)... 2015   Medisafe ™, the leading global medication ... iOS and Android smartphones and tablets, ... the platform to allow patients to track and correlate ... time, patients will be able to visualize in real-time ... biometrics, such as glucose levels and blood pressure. ...
(Date:3/26/2015)... March 26, 2015 The Granite ... recreation and athletic club, today announced it has implemented ... freedom of movement for members and staff, while restricting ... comprehensive process, we selected FST,s IMID Access system because ... for our members and staff, in addition to unparalleled ...
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
Other Contents